Latest Research And Development News

Tryptamine Therapeutics has locked in $2.6 million in non-dilutive funding to fast-track clinical trials of its lead psilocin-based therapy, TRP-8803, targeting binge eating disorder and other conditions.

VEEM Limited has renewed a six-year, $65 million contract to supply critical components for Australia's Collins Class submarines, reinforcing its long-standing defence partnership and projecting stronger financial performance in FY26.

Iress Limited reported a robust first half of 2025 with strong earnings growth and reduced leverage, driven by core business strength and strategic divestments. The company is poised to capitalize on regulatory tailwinds and technology demand in wealth and trading sectors.

Iress Limited has reported a 19% increase in underlying earnings per share for its continuing business in the first half of 2025, completing a major transformation and reaffirming its full-year guidance despite revenue pressures from divestments.

AnteoTech Ltd has received a $2.59 million cash rebate from the Australian Tax Office for its 2025 R&D activities, underscoring the success of its recent strategic initiatives.

Noxopharm Limited has successfully completed the second dose cohort in its HERACLES Phase 1 trial for SOF-SKN™, confirming safety and tolerability and moving forward to a higher dose. This progress marks a key step in developing a novel autoimmune disease treatment.

Invex Therapeutics reports a significantly reduced net loss for FY25, driven by lower R&D costs after closing its Phase III trial, while advancing promising pre-clinical Alzheimer’s research through a collaboration with Tessara Therapeutics.

ResMed Inc. reported a robust 10% increase in revenue to $5.15 billion for fiscal 2025, driven by strong demand in sleep and breathing health devices and residential care software. The company also expanded its diagnostic capabilities with the acquisition of VirtuOx, positioning itself for further growth in home-based health solutions.

Avita Medical reported an 18% revenue increase and a 30% reduction in net loss for the first half of 2025, signaling progress as it scales commercial operations and targets profitability by 2026.

AVITA Medical reported a 21% revenue increase in Q2 2025 driven by expanded sales and new product launches, yet continues to face net losses and liquidity challenges requiring loan covenant waivers.

Papyrus Australia appoints Daniel Schmidt as CEO to lead its transition from R&D to commercial operations, alongside a strategic restructure to support growth.

HeraMED Limited has resumed trading on the ASX following the release of its quarterly reports and a significant capital raising announcement, marking a pivotal moment for the medical device company.